Quick Answer
Inhibrx Biosciences, Inc. reported Diluted EPS of $9.04 per share (loss) for fiscal year 2025.
Inhibrx Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$9.04 | -108.0% |
| 2024 | $112.62 | +649.9% |
| 2023 | -$20.48 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.28 | +19.7% | -23.2% |
| June 30, 2025 | -$1.85 | -101.5% | +33.9% |
| March 31, 2025 | -$2.80 | +51.5% | +1.4% |
| September 30, 2024 | -$2.84 | +35.3% | -102.3% |
| June 30, 2024 | $125.48 | +3011.4% | +2274.7% |
| March 31, 2024 | -$5.77 | — | -31.4% |
| September 30, 2023 | -$4.39 | — | -1.9% |
| June 30, 2023 | -$4.31 | — | — |
- Inhibrx Biosciences, Inc. showed a decrease of -108.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s diluted eps has grown by 55.9% (from $20.48 per share (loss) to $9.04 per share (loss)).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: